Open main menu
Home
Random
Recent changes
Special pages
Community portal
Preferences
About Wikipedia
Disclaimers
Incubator escapee wiki
Search
User menu
Talk
Dark mode
Contributions
Create account
Log in
Editing
Linezolid
(section)
Warning:
You are not logged in. Your IP address will be publicly visible if you make any edits. If you
log in
or
create an account
, your edits will be attributed to your username, along with other benefits.
Anti-spam check. Do
not
fill this in!
===Specific populations=== In adults and children over the age of 12, linezolid is usually given every 12 hours, whether orally or intravenously.<ref name=Moellering/><ref name="American Family Physician"/> In younger children and infants, it is given every eight hours.<ref name=Buck>{{cite journal | vauthors = Buck ML |title=Linezolid use for resistant Gram-positive infections in children |journal=Pediatric Pharmacotherapy |volume=9 |issue=6 |date=June 2003 |url=http://www.healthsystem.virginia.edu/alive/pediatrics/PharmNews/200306.pdf |access-date=8 June 2009 |url-status=dead |archive-url=https://web.archive.org/web/20110605115607/http://www.healthsystem.virginia.edu/alive/pediatrics/PharmNews/200306.pdf |archive-date=5 June 2011 }}</ref> No dosage adjustments are required in the elderly, in people with mild-to-moderate liver failure, or in those with impaired kidney function.<ref name=Lexi-Comp/> In people requiring [[hemodialysis]], care should be taken to give linezolid after a session, because dialysis removes 30β40% of a dose from the body; no dosage adjustments are needed in people undergoing [[hemofiltration|continuous hemofiltration]],<ref name=Lexi-Comp/> although more frequent administration may be warranted in some cases.<ref name=Herrmann/> According to one study, linezolid may need to be given more frequently than normal in people with [[burn]]s affecting more than 20% of [[total body surface area|body area]], due to increased nonrenal clearance of the drug.<ref>{{cite journal |vauthors=Lovering AM, Le Floch R, Hovsepian L, etal |title=Pharmacokinetic evaluation of linezolid in patients with major thermal injuries |journal=Journal of Antimicrobial Chemotherapy |volume=63 |issue=3 |pages=553β9 |date=March 2009 |pmid=19153078 |doi=10.1093/jac/dkn541 |issn=0305-7453|doi-access=free }}</ref> Linezolid is in U.S. [[pregnancy category]] C, meaning there have been no adequate studies of its safety when used by pregnant women, and although animal studies have shown mild toxicity to the fetus, the benefits of using the drug may outweigh its risks.<ref name="Zyvox FDA label" /> It also passes into [[breast milk]], although the clinical significance of this (if any) is unknown.<ref name=InfectiousDiseases/>
Edit summary
(Briefly describe your changes)
By publishing changes, you agree to the
Terms of Use
, and you irrevocably agree to release your contribution under the
CC BY-SA 4.0 License
and the
GFDL
. You agree that a hyperlink or URL is sufficient attribution under the Creative Commons license.
Cancel
Editing help
(opens in new window)